Oncolytics Biotech® Announces Fireside Chat at the Cantor Global Healthcare Conference

Company management will also be participating in one-on-one investor meetings at the conference. To schedule a meeting, please submit a request on the conference website, contact your Cantor Fitzgerald representative, or email jpatton@oncolytics.ca. Company management will also be participating in one-on-one investor meetings at the conference. To schedule a meeting, please submit a request on the conference website, contact your Cantor Fitzgerald representative, or emailjpatton@oncolytics...

Company management will also be participating in one-on-one investor meetings at the conference. To schedule a meeting, please submit a request on the conference website, contact your Cantor Fitzgerald representative, or email jpatton@oncolytics.ca.

A live webcast of the Company's presentation will also be available on the Investor Relations page of Oncolytics' website (LINK) and will be archived for three months.

About Oncolytics Biotech Inc.

Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in phase 2 studies in breast and pancreatic cancers. It acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype -- turning "cold" tumors "hot" -- through innate and adaptive immune responses to treat a variety of cancers.

Pelareorep has demonstrated synergies with multiple approved oncology treatments. Oncolytics is currently conducting and planning combination clinical trials with pelareorep in solid and hematological malignancies as it advances towards registrational studies in metastatic breast cancer and pancreatic cancer. For further information, please visit: www.oncolyticsbiotech.com

Company Contact

Jon Patton
Director of IR & Communication
+1-858-886-7813
jpatton@oncolytics.ca

Investor Relations for Oncolytics

Timothy McCarthy
LifeSci Advisors
+1-917-679-9282
tim@lifesciadvisors.com

Logo: https://mma.prnewswire.com/media/1762876/3912638/Oncolytics_Biotech_New_Logo.jpg

 

View original content:https://www.prnewswire.co.uk/news-releases/oncolytics-biotech-announces-fireside-chat-at-the-cantor-global-healthcare-conference-301931546.html